BridgIT, a New Tool for Orphan and Novel Enzyme Reactions

Effective protein engineering can give us control over the generated products inside a cell. However, for many of the biochemical reactions responsible for these products, we don't we don't know the specific protein- or enzyme-producing gene responsible. These reactions are called "orphan" and have become a big problem for protein engineers.

Moreover, software that predicts novel, hypothetical biochemical reactions - a common tool for modern biochemists and synthetic biologists - cannot assign potential genes to them, meaning that there are no recorded DNA sequences that scientists can tweak to change protein or enzyme production. And to further complicate matters, there are also many "orphan" metabolic enzymes whose particular reaction is unknown, thus leaving important gaps in our maps of metabolic networks and pathways.

In short, finding which gene(s) correspond to the enzyme/protein(s) that catalyze an orphan or novel, hypothetical reaction has grown into a critical issue for applications ranging from biotechnology to medicine.

Fortunately, chemical engineers from the lab of Vassily Hatzimanikatis at EPFL have found a solution. The group developed a new computational method and online tool, called "BridgIT", to identify candidate genes and catalyzing proteins for orphan and novel, hypothetical reactions. All BridgIT needs to know is the four connecting bonds around the atoms of the reactive sites, and it can correctly annotate proteins for 93% of analyzed enzymatic reactions. This percentage rose to almost 100% when seven connecting bonds were included.

To test BridgIT's accuracy, the researchers pitted it against databases of reactions that were once orphan but have now been assigned to genes and enzymes - basically, reactions that have become "non-orphan". BridgIT predicted the exact or a highly related enzyme for 211 out of 234 reactions (>90%). And for hypothetical reactions that were once novel and have since been assigned enzymes, BridgIT found the exact enzymes for 334 out of 379 reactions (>88%).

The authors write: "BridgIT... will allow researchers to fill the knowledge gaps in metabolic networks and will act as a starting point for designing novel enzymes to catalyze non-natural transformations."

Noushin Hadadi, Homa MohammadiPeyhani, Ljubisa Miskovic, Marianne Seijo, Vassily Hatzimanikatis.
Enzyme annotation for orphan and novel reactions using knowledge of substrate reactive sites.
PNAS 25 March 2019. doi: 10.1073/pnas.1818877116.

Most Popular Now

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...

Are You Eligible for a Clinical Trial? C…

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates. Researchers...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...